Skip to main content
SpringerLink
Log in

Pharmacoeconomic data support early use of inhaled corticosteroids

  • Drug Economics and Quality of Life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Guidelines on the management of asthma. Thorax 1993; 48 Suppl.:Sl–24

    Google Scholar 

  2. Towards an international consensus on asthma management. Drug Ther Perspect 1993 Jan 25; 1(1): 7–10

    Google Scholar 

  3. Davis R, McTavish D. Budesonide: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in asthma. PharmacoEconomics 1995 May; 7(5): 457–70

    Article  PubMed  CAS  Google Scholar 

  4. McGill KA, Joseph B, Busse WW. Corticosteroids in the treatment of asthma: practical recommendations. Clin Immunother 1995 Jul; 4(1): 16–48

    Article  Google Scholar 

  5. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995 Mar 30; 868–75

    Google Scholar 

  6. 1995 Physicians GenRx. St. Louis, Missouri: Mosby-Year Book, Inc. 1995

  7. British National Formulary No. 29. London: The Pharmaceutical Press, 1995

  8. Bosman HG, van Uffelen R, Tamminga JJ, et al. Comparison of inhaled beclomethasone dipropionate 1000µg twice daily and oral prednisone 10mg once daily in asthmatic patients Thorax 1994; 49: 37–40

    Article  PubMed  CAS  Google Scholar 

  9. Weiss KB, Sullivan SD. The economic costs of asthma: a review and conceptual model. PharmacoEconomics 1993 Jul; 4(1): 14–30

    Article  PubMed  CAS  Google Scholar 

  10. Mellis CM, Peat JK, Woolcock AJ. The cost of asthma: can it be reduced? PharmacoEconomics 1993 Mar; 3(3): 205–19

    Article  PubMed  CAS  Google Scholar 

  11. Rutten-van Mölken MPMH, Van Doorslaer EKA, Jansen MCC, et al. Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma. PharmacoEconomics 1993 Oct; 4(4): 257–70

    Article  PubMed  Google Scholar 

  12. Rutten-van Mölken MPMH, Van Doorslaer EKA, Jansen MCC, et al. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151 Apr: 975–82

    PubMed  Google Scholar 

  13. Connet GJ, Lenney W, McConchie SM. The cost effectiveness of budesonide in severe asthmatics aged one to three years. Br J Med Econ 1993; 6: 127–34

    Google Scholar 

  14. Juniour EF. Quality-of-life considerations in the treatment of asthma. PharmacoEconomics 1995 Aug; 8(2): 123–38

    Article  Google Scholar 

  15. Okamoto LJ, Mahajan P, Schaberg A, et al. Effects of inhaled fluticasone propionate powder on quality of life of patients with asthma [abstract]. J Allergy Clin Immunol 1995 Jan; 95(Part 2): 313

    Google Scholar 

  16. van Schayck CP, Dompeling E, Rutten MPMH, et al. The influence of an inhaled steroid on quality of life in patients with asthma or COPD. Chest 1995 May; 107(5): 1199–205

    Article  PubMed  Google Scholar 

  17. Hyland ME, Crocker GR. Validation of an asthma quality of life diary in a clinical trial. 1995 Jul; Thorax 50: 724–30

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pharmacoeconomic data support early use of inhaled corticosteroids. Drugs Ther. Perspect 6, 13–16 (1995). https://doi.org/10.2165/00042310-199506090-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199506090-00006

Search

Navigation